Epigenetic Drug and Diagnostic Technology Market Report: Trends, Forecast and Competitive Analysis to 2030

Epigenetic Drug and Diagnostic Technology Market Report: Trends, Forecast and Competitive Analysis to 2030

Epigenetic Drug and Diagnostic Technology Trends and Forecast

The future of the global epigenetic drug and diagnostic technology market looks promising with opportunities in the oncology and non-oncology markets. The global epigenetic drug and diagnostic technology market is expected to reach an estimated $27.7 billion by 2030 with a CAGR of 19.2% from 2024 to 2030. The major drivers for this market are rising prevalence of chronic diseases like cancer and neurological disorders, surge in geriatric population, and innovations of new epigenetic drugs and diagnostics technologies.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Epigenetic Drug and Diagnostic Technology by Segment

The study includes a forecast for the global epigenetic drug and diagnostic technology by type of therapy, technology, application, and region.

Epigenetic Drug and Diagnostic Technology Market by Type of Therapy [Shipment Analysis by Value from 2018 to 2030]:

• HDAC
• DNMT

Epigenetic Drug and Diagnostic Technology Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

• DNA Methylation
• Histone Methylation
• Histone Acetylation
• Large Noncoding RNA
• Microrna Modification
• Chromatin Structures

Epigenetic Drug and Diagnostic Technology Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Oncology
• Non-Oncology

Epigenetic Drug and Diagnostic Technology Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Epigenetic Drug and Diagnostic Technology Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies epigenetic drug and diagnostic technology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the epigenetic drug and diagnostic technology companies profiled in this report include-

• Roche Diagnostics
• Thermo Fisher Scientific
• Eisai
• Novartis
• Illumina
• Merck Sharp & Dohme
• Qiagen

Epigenetic Drug and Diagnostic Technology Market Insights

Lucintel forecasts that DNMT will remain the larger segment over the forecast period due to wide-scale availability.

Within this market, oncology will remain the larger segment due to high growth of cancer and rising number of deaths caused by cancer.

North America will remain the largest region over the forecast period due to presence of well established healthcare facilities and surge in geriatric population in the region.

Features of the Global Epigenetic Drug and Diagnostic Technology Market

Market Size Estimates: Epigenetic drug and diagnostic technology market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Epigenetic drug and diagnostic technology market size by type of therapy, technology, application, and region in terms of value ($B).

Regional Analysis: Epigenetic drug and diagnostic technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type of therapy, technologies, applications, and regions for the epigenetic drug and diagnostic technology market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the epigenetic drug and diagnostic technology market.

Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the epigenetic drug and diagnostic technology market size?

Answer: The global epigenetic drug and diagnostic technology market is expected to reach an estimated $27.7 billion by 2030.

Q2. What is the growth forecast for epigenetic drug and diagnostic technology market?

Answer: The global epigenetic drug and diagnostic technology market is expected to grow with a CAGR of 19.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the epigenetic drug and diagnostic technology market?

Answer: The major drivers for this market are rising prevalence of chronic diseases like cancer and neurological disorders, surge in geriatric population, and innovations of new epigenetic drugs and diagnostics technologies.

Q4. What are the major segments for epigenetic drug and diagnostic technology market?

Answer: The future of the epigenetic drug and diagnostic technology market looks promising with opportunities in the oncology and non-oncology markets.

Q5. Who are the key epigenetic drug and diagnostic technology market companies?

Answer: Some of the key epigenetic drug and diagnostic technology companies are as follows:

• Roche Diagnostics
• Thermo Fisher Scientific
• Eisai
• Novartis
• Illumina
• Merck Sharp & Dohme
• Qiagen

Q6. Which epigenetic drug and diagnostic technology market segment will be the largest in future?

Answer: Lucintel forecasts that DNMT will remain the larger segment over the forecast period due to wide-scale availability.

Q7. In epigenetic drug and diagnostic technology market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to presence of well established healthcare facilities and surge in geriatric population in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the epigenetic drug and diagnostic technology market by type of therapy (HDAC and DNMT), technology (DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microrna modification, and chromatin structures), application (oncology and non-oncology), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2. Which segments will grow at a faster pace and why?

Q.3. Which region will grow at a faster pace and why?

Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?

Q.5. What are the business risks and competitive threats in this market?

Q.6. What are the emerging trends in this market and the reasons behind them?

Q.7. What are some of the changing demands of customers in the market?

Q.8. What are the new developments in the market? Which companies are leading these developments?

Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?

Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?

Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Please note: It will take 2-3 business days to deliver the report upon receipt the order.